The immune checkpoint inhibitor Opdivo (nivolumab) may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 clinical trial suggest. A three-year survival analysis of the trial, called ATTRACTION-2 (NCT02267343), showed that the treatment significantly extended patients’ lives and the time they … Continue reading Opdivo Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show